Table 5.
Logistic regression to study the risk of hospital death among cancer patients hospitalized in France for COVID-19 (from 1 March 2020 to 30 April 2020), using colorectal cancers as the reference group.
| n | Death | Hospital Mortality Rate | OR | p-Value | aOR * | p-Value | |
|---|---|---|---|---|---|---|---|
| All Cancer | |||||||
| Colorectal | 518 | 142 | 27.4 | ref | – | ref | – |
| Digestive (non-colorectal) | 626 | 233 | 37.2 | 1.6 [1.2–2.0] | <0.01 | 1.6 [1.3–2.1] | <0.01 |
| Breast | 561 | 133 | 23.7 | 0.8 [0.6–1.1] | 0.16 | 1.0 [0.8–1.4] | 0.76 |
| Prostate | 621 | 188 | 30.3 | 1.2 [0.9–1.5] | 0.29 | 0.9 [0.7–1.2] | 0.36 |
| Lung | 873 | 359 | 41.1 | 1.8 [1.5–2.3] | <0.01 | 2.0 [1.6–2.6] | <0.01 |
| Urinary tract | 363 | 122 | 33.6 | 1.3 [1.0–1.8] | 0.049 | 1.2 [0.9–1.7] | 0.15 |
| Female genital organs | 185 | 54 | 29.2 | 1.1 [0.8–1.6] | 0.64 | 1.4 [0.9–2.1] | 0.07 |
| Lip, oral cavity and pharynx | 162 | 38 | 23.5 | 0.8 [0.5–1.2] | 0.32 | 0.9 [0.6–1.4] | 0.73 |
| Skin | 121 | 32 | 26.5 | 1.0 [0.6–1.5] | 0.83 | 0.8 [0.5–1.3] | 0.44 |
| Other cancers ** | 303 | 82 | 27.1 | 1.0 [0.7–1.3] | 0.91 | 1.2 [0.8–1.6] | 0.37 |
| Hematological | 1389 | 470 | 33.8 | 1.4 [1.1–1.7] | 0.01 | 1.4 [1.1–1.8] | <0.01 |
| Solid Cancer with metastasis | |||||||
| Colorectal | 244 | 84 | 34.4 | ref | – | ref | – |
| Digestive (non-colorectal) | 244 | 109 | 44.7 | 1.5 [1.1–2.2] | 0.02 | 1.6 [1.1–2.3] | 0.02 |
| Breast | 241 | 77 | 32.0 | 0.9 [0.6–1.3] | 0.56 | 1.1 [0.8–1.7] | 0.52 |
| Prostate | 196 | 74 | 37.8 | 1.2 [0.8–1.7] | 0.47 | 0.9 [0.6–1.3] | 0.73 |
| Lung | 461 | 215 | 46.6 | 1.7 [1.2–2.3] | <0.01 | 1.7 [1.2–2.4] | <0.01 |
| Urinary tract | 128 | 54 | 42.2 | 1.4 [0.9–2.2] | 0.14 | 1.4 [0.9–2.1] | 0.15 |
| Female genital organs | 119 | 41 | 34.5 | 1.0 [0.6–1.6] | 0.99 | 1.2 [0.7–2.0] | 0.44 |
| Lip, oral cavity and pharynx | 45 | 12 | 26.7 | 0.7 [0.3–1.4] | 0.31 | 0.7 [0.4–1.5] | 0.37 |
| Skin | 43 | 12 | 27.9 | 0.7 [0.4–1.5] | 0.41 | 0.7 [0.4–1.5] | 0.41 |
| Other cancers ** | 54 | 15 | 27.8 | 0.7 [0.4–1.4] | 0.35 | 0.8 [0.4–1.6] | 0.53 |
| Solid Cancer without metastasis | |||||||
| Colorectal | 274 | 58 | 21.2 | ref | – | ref | – |
| Digestive (non-colorectal) | 382 | 124 | 32.5 | 1.8 [1.2–2.6] | <0.01 | 2.0 [1.3–3.0] | <0.01 |
| Breast | 320 | 56 | 17.5 | 0.8 [0.5–1.2] | 0.26 | 1.1 [0.7–1.7] | 0.63 |
| Prostate | 425 | 114 | 26.8 | 1.4 [0.9–2.0] | 0.09 | 1.0 [0.7–1.4] | 0.93 |
| Lung | 412 | 144 | 35.0 | 2.0 [1.4–2.9] | <0.01 | 2.4 [1.7–3.5] | <0.01 |
| Urinary tract | 235 | 68 | 28.9 | 1.5 [1.0–2.3] | 0.04 | 1.3 [0.9–2.0] | 0.20 |
| Female genital organs | 66 | 13 | 19.7 | 0.9 [0.5–1.8] | 0.79 | 1.4 [0.7–2.9] | 0.32 |
| Lip, oral cavity and pharynx | 117 | 26 | 22.2 | 1.1 [0.6–1.8] | 0.82 | 1.5 [0.9–2.6] | 0.12 |
| Skin | 78 | 20 | 25.6 | 1.3 [0.7–2.3] | 0.40 | 1.0 [0.5–1.8] | 0.91 |
| Other cancers ** | 249 | 67 | 26.9 | 1.4 [0.9–2.1] | 0.13 | 2.0 [1.3–3.0] | <0.01 |
OR: odds ratio; aOR: adjusted odds ratio. * adjusted on age, sex, dementia, heart failure, chronic respiratory disease, cirrhosis, diabetes, deficiency anemia and pulmonary bacterial infection. ** including mesothelial and soft issue, respiratory and intrathoracic organs (except lung), bone and articular cartilage, endocrine glands, other male cancers and central nervous system.